CHARLOTTE, N.C., June 3, 2010 (GLOBE NEWSWIRE) — Chelsea Therapeutics
International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 9th Annual
Needham Healthcare Conference at 2:00 PM ET on Wednesday June 9, 2010 at the New
York Palace Hotel in New York City.
Dr. Simon Pedder, Chelsea’s president and chief executive officer, will provide
a brief overview of the company’s product pipeline, clinical development status
and upcoming milestones.
Dr. Pedder’s presentation will be webcast live and archived for 30 days on
Chelsea’s website, www.chelseatherapeutics.com.
About Chelsea Therapeutics
Chelsea Therapeutics is a biopharmaceutical development company that acquires
and develops innovative products for the treatment of a variety of human
diseases. Chelsea’s most advanced drug candidate, Northera(TM) (droxidopa), is
an orally active synthetic precursor of norepinephrine initially being developed
for the treatment of neurogenic orthostatic hypotension. In addition to
Northera, Chelsea is also developing a portfolio of metabolically inert oral
antifolate molecules engineered to have potent anti-inflammatory and anti-tumor
activity to treat a range of immunological disorders, including two clinical
stage product candidates: CH-1504 and CH-4051. Preclinical and clinical data
suggest superior safety and tolerability, as well as increased potency versus
This press release contains forward-looking statements regarding future events.
These statements are just predictions and are subject to risks and uncertainties
that could cause the actual events or results to differ materially. These risks
and uncertainties include risks and costs of drug development, risk of
regulatory approvals, our reliance on our lead drug candidates droxidopa and
CH-4051, reliance on collaborations and licenses, intellectual property risks,
our need to raise additional operating capital in the future, our history of
losses, competition, market acceptance for our products if any are approved for
marketing, and reliance on key personnel including specifically Dr. Pedder.
CONTACT: Chelsea Therapeutics